Korean Circ J.  2007 May;37(5):187-190. 10.4070/kcj.2007.37.5.187.

High Density Lipoprotein Cholesterol Comes of Age

• Cho H

• KMID: 2227062
• DOI: http://doi.org/10.4070/kcj.2007.37.5.187

Abstract

Despite the excellent success of lowering low-density lipoprotein cholesterol (LDLc) cholesterol for treating coronary heart disease (CHD), a major part of the population still suffer from CHD. This fact is more prominent among the high risk patients who receive lipid lowering treatment with statins. This treatment is based on the prevailing view that LDL cholesterol (LDLc) is the only important risk factor for CHD. It is well known that HDL plays a crucial role for preventing CHD. Several epidemiologic studies and clinical trials have reported that high density lipoprotein cholesterol (HDLc) is an independent risk factor for CHD as well. A large scale meta-analysis of clinical trials clearly supports that increasing HDLc is equally important as decreasing LDLc, suggesting that physicians should pay attention to increasing HDLc as well as decreasing LDLc. Ongoing trials that are focused on this issue will test this hypothesis in the near future.

Keyword

LDL cholesterol; HDL cholesterol; Coronary heart disease

MeSH Terms

Cholesterol
Cholesterol, HDL*
Cholesterol, LDL
Coronary Disease
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoproteins
Risk Factors
Cholesterol
Cholesterol, HDL
Cholesterol, LDL
Lipoproteins

Figure

• 

  Fig. 1 Relation between the proportional reduction in the incidence of major coronary events and mean absolute low-density lipoprotein (LDL) cholesterol reduction at 1 year.15)

• 

  Fig. 2 LDL cholesterol distribution between coronary heart disease (CHD) patients and normal controls.16) LDLc: low-density lipoprotein cholesterol.

• 

  Fig. 3 Effect of various drug classes on trial primary clinical event rate.26) HDL: high-density lipoprotein, LDL: low-density lipoprotein.

Reference

1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?: findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986. 256:2823–2828.

2. Keys A, Menotti A, Aravanis C, et al. The seven countries study: 2,289 deaths in 15 years. Prev Med. 1984. 13:141–154.

3. Hong SJ, Oh DJ, Kim EJ, et al. The comparison of seru lipid levels and risk factors according to the status of coronary atherosclerosis in Koreans. Korean Circ J. 2003. 33:465–474.

4. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005. 352:1425–1435.

5. Cannon CP, Murphy SA, Braunwald E. Intensive lipid lowering with atorvastatin in coronary disease. N Engl J Med. 2005. 353:93–96.

6. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005. 165:725–730.

7. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2004. 117:596–606.

8. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther. 2004. 2:485–501.

9. Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet. 1994. 344:1383–1389.

10. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998. 97:1440–1445.

11. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE ) trial. Circulation. 1998. 98:2513–2519.

12. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998. 339:1349–1357.

13. Heart Protection Study Collaborators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002. 360:7–22.

14. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER ): a randomised controlled trial. Lancet. 2002. 360:1623–1630.

15. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005. 366:1267–1278.

16. Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992. 19:792–802.

17. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (THE INTERHEART STUDY): case-control study. Lancet. 2004. 364:937–952.

18. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977. 62:707–714.

19. Cho EY, Bae SJ, Cho HK, et al. Association of cholesteryl ester transfer protein gene polymorphism with serum lipid concentration and coronary artery disease in Korean men. Korean Circ J. 2004. 34:565–573.

20. Cho DK, Kwon SU, Kim SW, et al. Risk factors and predictors for the progression of carotid atherosclerotic stenosis in Korean Adults. Korean Circ J. 2005. 35:834–840.

21. Bae JH, Seun KB, Jung HO, et al. Analysis of Korean carotid intima-media thickness in Korean healthy subjects and patients with risk factors: Korean Multi-Center Epidemiologic Study. Korean Circ J. 2005. 35:513–524.

22. Brewer HB Jr. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004. 24:387–391.

23. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM ): results of follow-up at 8 years. Eur Heart J. 1998. 19:Suppl A. A2–A11.

24. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy. Am J Med. 1991. 90:11–16.

25. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989. 79:8–15.

26. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol. 2006. 17:631–636.